Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by StockingUp21on Apr 23, 2021 7:16pm
133 Views
Post# 33060112

RE:RE:A couple of "stupid" questions

RE:RE:A couple of "stupid" questions

The biggest beneficiar of the IP amalgamation will be for the owner, not me and you who stupidly bought thinking we own chunk of that. 


Actuarial wrote: I would not call amalgamation a new dilution. Simply because when you put something to share holder's equity on the right side of the balance sheet, you also put something to assets (intangible) on the left side of the balance sheet. It is more alike a M&A or partnership deal, i.e., AH inject some assets into ATE and at the same time and then share profits latter. Or, alike convertable debt to ATE. The profit sharing right of AH was there from the beginning of the ATE and now it will be explicit rather than implicit. Regardless of amalgamation or not, ATE can not simply sell the company to Merck and then give all the money to current share holders without paying AH a penny. It is not going to happen. Never.

 

<< Previous
Bullboard Posts
Next >>